Evidence map›Paper›PMID 37559381›Full record

ArticleDrug delivery2023

Oral delivery of nerolidol alleviates cyclophosphamide-induced renal inflammation, apoptosis, and fibrosis via modulation of NF-κB/cleaved caspase-3/TGF-β signaling molecules.

Ashif Iqubal, Abul Kalam Najmi, Shadab Md, Huda Mohammed Alkreathy, Javed Ali, Mansoor Ali Syed, Syed Ehtaishamul Haque

Open access · goldAbstract read
In one paragraph

Article in Drug delivery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Renoprotective Effects ofIranian journal of pharmaceutical research : IJPR
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Ashif IqubalDepartment of Pharmacology, School of Pharmaceutical Education and Research, New Delhi, India.
Abul Kalam NajmiDepartment of Pharmacology, School of Pharmaceutical Education and Research, New Delhi, India.
Shadab MdDepartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Huda Mohammed AlkreathyDepartment of Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Javed AliDepartment of Pharmaceutics, School of Pharmaceutical Education and Research, New Delhi, India.
Mansoor Ali SyedDepartment of Biotechnology, Jamia Millia Islamia, New Delhi, India.
Syed Ehtaishamul HaqueDepartment of Pharmacology, School of Pharmaceutical Education and Research, New Delhi, India.
Delhi Pharmaceutical Science and Research University · INKing Abdulaziz University · SAJamia Millia Islamia · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cyclophosphamide (CP) is one of the most extensively used antineoplastic drug, but the nephrotoxicity caused by this drug is a major limiting factor for its use. Nerolidol (NERO) is a natural bioactive compound with diverse pharmacological actions.

Indexed as

KidneyNF-kappa BAnimalsApoptosisCaspase 3CyclophosphamideFibrosisInflammationMiceOxidative StressSesquiterpenesUreaCaspase 3CyclophosphamidenerolidolNF-kappa BSesquiterpenesUreaNephrotoxicityoxidative stressrenal fibrosis and inflammation

Identifiers

PMID37559381
PMCPMC10946274
OpenAlexW4385716684

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.